2022
DKA Prevention and Insulin Pumps: Lessons Learned From a Large Pediatric Pump Practice
Doyle EA, Weinzimer SA, Tamborlane W. DKA Prevention and Insulin Pumps: Lessons Learned From a Large Pediatric Pump Practice. The Science Of Diabetes Self-Management And Care 2022, 48: 476-482. PMID: 36129121, DOI: 10.1177/26350106221125699.Peer-Reviewed Original ResearchConceptsContinuous glucose monitorHigher A1C levelsA1c levelsDKA eventsInsulin pumpPump usersPump-treated patientsRetrospective chart reviewPediatric endocrinology practiceType 1 diabetesInsulin pump usersConcurrent illnessDKA preventionPump patientsDiabetes durationDKA episodesMean A1CChart reviewEndocrinology practiceDKA ratesDKA severityMean ageInsulin omissionMost episodesPatientsSGLT2i Improves Glycemic Control in Patients With Congenital Severe Insulin Resistance.
Galderisi A, Tamborlane W, Taylor SI, Attia N, Moretti C, Barbetti F. SGLT2i Improves Glycemic Control in Patients With Congenital Severe Insulin Resistance. Pediatrics 2022, 150 PMID: 35652305, DOI: 10.1542/peds.2021-055671.Peer-Reviewed Original ResearchConceptsRabson-Mendenhall syndromeGlycemic controlHemoglobin A1cRenal calcium excretionInsulin-resistant diabetesSevere insulin resistanceCalcium excretionUrinary calciumAntidiabetic treatmentDay doseDose escalationSecond patientFirst patientInsulin levelsInsulin resistanceUrinary excretionSerum glucosePatientsEmpagliflozinMild increaseDapagliflozinΒ-hydroxybutyrateTarget rangeA1CExcretion
2018
Eligibility for clinical trials is limited for youth with type 2 diabetes: Insights from the Pediatric Diabetes Consortium T2D Clinic Registry
Tamborlane WV, Chang P, Kollman C, Klingensmith GJ, Ruedy K, Gal RL, Van Name M, Bacha F, Willi S, Beck RW, Consortium F. Eligibility for clinical trials is limited for youth with type 2 diabetes: Insights from the Pediatric Diabetes Consortium T2D Clinic Registry. Pediatric Diabetes 2018, 19: 1379-1384. PMID: 30175440, DOI: 10.1111/pedi.12763.Peer-Reviewed Original ResearchConceptsType 2 diabetesT2D durationT2D patientsClinical trialsEligibility criteriaPlacebo-assigned subjectsPercentage of patientsCurrent clinical trialsRestrictive eligibility criteriaBaseline HbA1cHbA1c levelsClinical characteristicsClinic registryRegistry enrollmentInvestigational treatmentPatientsCurrent trialTrialsNew drugsMonthsHbA1cRatio of femaleDiabetesRegistryEnrollmentThe present and future treatment of pediatric type 2 diabetes
Van Name MA, Guandalini C, Steffen A, Patel A, Tamborlane W. The present and future treatment of pediatric type 2 diabetes. Expert Review Of Endocrinology & Metabolism 2018, 13: 207-212. PMID: 30063424, DOI: 10.1080/17446651.2018.1499467.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsType 2 diabetesPediatric type 2 diabetesStandard initial treatmentMetformin monotherapyPediatric T2DClinical outcomesInitial treatmentPediatric populationClinical trialsRapid progressionInjectable agentsFuture treatmentMetabolic controlT2DDiabetesNew drugsInsulinPhase 3DrugsRegulatory approvalT2D.TreatmentPatientsMetforminCurrent useAn Effective Diabetic Ketoacidosis Prevention Intervention in Children With Type 1 Diabetes
Vitale RJ, Card CE, Lichtman JH, Weyman K, Michaud C, Sikes K, Tamborlane WV, Weinzimer SA. An Effective Diabetic Ketoacidosis Prevention Intervention in Children With Type 1 Diabetes. SAGE Open Nursing 2018, 4: 2377960818804742. PMID: 33415207, PMCID: PMC7774356, DOI: 10.1177/2377960818804742.Peer-Reviewed Original ResearchSick-day managementEmergency department visitsDiabetic ketoacidosisDepartment visitsSymptoms of DKAEarly outpatient interventionEducational interventionShort educational interventionBrief refresher courseKnowledge of signsSame knowledge questionnaireParents of childrenTreatment modalitiesOutpatient interventionPrevention interventionsPatient recognitionKnowledge questionnaireType 1Sick daysEarly warning signsDay managementInterventionPatientsWarning signsSymptoms
2017
Pharmacokinetics and pharmacodynamics of canagliflozin in pediatric patients with type 2 diabetes
Tamborlane WV, Polidori D, Argenti D, Di Prospero NA. Pharmacokinetics and pharmacodynamics of canagliflozin in pediatric patients with type 2 diabetes. Pediatric Diabetes 2017, 19: 649-655. PMID: 29271103, DOI: 10.1111/pedi.12626.Peer-Reviewed Original ResearchConceptsUrinary glucose excretionCanagliflozin 100Type 2 diabetesCanagliflozin 300T2D patientsSodium-glucose cotransporter 2 inhibitorsGlucose cotransporter 2 inhibitorsPharmacodynamics of canagliflozinSingle daily doseCotransporter 2 inhibitorsTreatment of adultsBody mass indexMaximum plasma concentrationPlasma glucose levelsDose-dependent increasePlasma concentration curveDaily doseGlucose excretionPediatric patientsMass indexPlasma concentrationsRenal thresholdGlucose levelsBody weightPatientsRandomized, double‐blind, placebo‐controlled dose‐finding study of the dipeptidyl peptidase‐4 inhibitor linagliptin in pediatric patients with type 2 diabetes
Tamborlane WV, Laffel LM, Weill J, Gordat M, Neubacher D, Retlich S, Hettema W, Hoesl CE, Kaspers S, Marquard J. Randomized, double‐blind, placebo‐controlled dose‐finding study of the dipeptidyl peptidase‐4 inhibitor linagliptin in pediatric patients with type 2 diabetes. Pediatric Diabetes 2017, 19: 640-648. PMID: 29171139, DOI: 10.1111/pedi.12616.Peer-Reviewed Original ResearchConceptsDPP-4 inhibitionDipeptidyl peptidase-4 inhibitor linagliptinType 2 diabetesInhibitor linagliptinAdult patientsPediatric patientsPlacebo-controlled dose-finding studyDrug-related adverse eventsPrimary efficacy endpointParallel-group studyWeeks of treatmentDose-finding studyDose-dependent reductionEfficacy endpointMean HbA1cAdverse eventsFPG levelsTrough levelsClinical efficacySafety profilePlasma glucosePharmacodynamic endpointsStudy populationPatientsLinagliptinPredictors of Loss to Follow-Up among Children with Type 2 Diabetes
Shoemaker A, Cheng P, Gal RL, Kollman C, Tamborlane WV, Klingensmith GJ, Clements MA, Hannon TS, Heptulla R, Less J, Wood J. Predictors of Loss to Follow-Up among Children with Type 2 Diabetes. Hormone Research In Paediatrics 2017, 87: 377-384. PMID: 28505610, DOI: 10.1159/000475595.Peer-Reviewed Original ResearchConceptsType 2 diabetesMultivariable logistic regression modelPediatric diabetes centersPredictors of lossLogistic regression modelsRace/ethnicityClinical factorsDiabetes CenterPoor complianceOdds ratioMedical careEnrollment variablesSignificant predictorsSocioeconomic factorsOlder adolescentsT2DDiabetesPatientsClinicCareRegression modelsParent educationPredictorsYearsFinal model
2016
Youth-Onset Type 2 Diabetes Consensus Report: Current Status, Challenges, and Priorities
Nadeau KJ, Anderson BJ, Berg EG, Chiang JL, Chou H, Copeland KC, Hannon TS, Huang T, Lynch JL, Powell J, Sellers E, Tamborlane WV, Zeitler P. Youth-Onset Type 2 Diabetes Consensus Report: Current Status, Challenges, and Priorities. Diabetes Care 2016, 39: 1635-1642. PMID: 27486237, PMCID: PMC5314694, DOI: 10.2337/dc16-1066.Peer-Reviewed Original ResearchConceptsType 2 diabetesConsensus reportYouth-Onset Type 2Current therapeutic optionsRisk of complicationsUnique pathophysiologyTherapeutic optionsIncreasing burdenVulnerable patientsAdult diseaseDiabetesType 2New treatmentsPsychosocial impactType 1Young adultsPrevention approachesTreatmentDiseaseAdultsChildrenAdvocacy groupsReportComplicationsPatientsUtility of Psychological Screening of Young Adults with Type 1 Diabetes Transitioning to Adult Providers
Quinn SM, Ambrosino JM, Doyle EA, Weyman K, Tamborlane WV, Jastreboff AM. Utility of Psychological Screening of Young Adults with Type 1 Diabetes Transitioning to Adult Providers. Endocrine Practice 2016, 22: 1104-1110. PMID: 27295017, DOI: 10.4158/ep151190.or.Peer-Reviewed Original ResearchConceptsChart reviewEating Problem SurveyDiabetes distressAdditional patientsYoung adultsDepressive symptomsProblem SurveyPoor glycemic controlDiabetes Eating Problem SurveyBody mass indexDiabetes Distress ScalePatient Health QuestionnaireType 1 diabetesTransition clinicGlycemic controlMass indexPHQ-8Formal screeningAdult providersGlycated hemoglobinSymptomatic depressionAdult careHealth QuestionnaireMetabolic controlPatientsAmerican Association Of Clinical Endocrinologists And American College Of Endocrinology 2016 Outpatient Glucose Monitoring Consensus Statement
Bailey TS, Grunberger G, Bode BW, Handelsman Y, Hirsch IB, Jovanovič L, Roberts V, Rodbard D, Tamborlane WV, Walsh J. American Association Of Clinical Endocrinologists And American College Of Endocrinology 2016 Outpatient Glucose Monitoring Consensus Statement. Endocrine Practice 2016, 22: 231-262. PMID: 26848630, DOI: 10.4158/ep151124.cs.Peer-Reviewed Original Research
2012
The Landmark JDRF Continuous Glucose Monitoring Randomized Trials: a Look Back at the Accumulated Evidence
Ruedy KJ, Tamborlane WV, for the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. The Landmark JDRF Continuous Glucose Monitoring Randomized Trials: a Look Back at the Accumulated Evidence. Journal Of Cardiovascular Translational Research 2012, 5: 380-387. PMID: 22538483, DOI: 10.1007/s12265-012-9364-9.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultBiomarkersBlood GlucoseBlood Glucose Self-MonitoringChildDiabetes Mellitus, Type 1Equipment DesignEvidence-Based MedicineGlycated HemoglobinHumansHypoglycemiaHypoglycemic AgentsMulticenter Studies as TopicPatient SatisfactionPredictive Value of TestsRandomized Controlled Trials as TopicTime FactorsTreatment OutcomeUnited StatesYoung AdultConceptsContinuous glucose monitorRandomized trialsT1D managementMulticenter Randomized TrialType 1 diabetesStandard glucose monitoringPrimary studiesComplications TrialSevere hypoglycemiaHemoglobin levelsDiabetes controlBiochemical hypoglycemiaCGM usePatientsGlucose monitoringAccumulated evidenceSecondary studiesReduced exposureTrialsA1CHypoglycemiaGlucose monitorSubjectsDCCTDiabetes
2010
Statement by the American Association of Clinical Endocrinologists Consensus Panel on Continuous Glucose Monitoring
Blevins TC, Bode BW, Garg SK, Grunberger G, Hirsch IB, Jovanovič L, Nardacci E, Orzeck EA, Roberts VL, Tamborlane WV, Rothermel C. Statement by the American Association of Clinical Endocrinologists Consensus Panel on Continuous Glucose Monitoring. Endocrine Practice 2010, 16: 730-745. PMID: 21356637, DOI: 10.4158/ep.16.5.730.Peer-Reviewed Original Research
2008
Comparison of Glycemic Variability Associated With Insulin Glargine and Intermediate-Acting Insulin When Used as the Basal Component of Multiple Daily Injections for Adolescents With Type 1 Diabetes
White NH, Chase HP, Arslanian S, Tamborlane WV, . Comparison of Glycemic Variability Associated With Insulin Glargine and Intermediate-Acting Insulin When Used as the Basal Component of Multiple Daily Injections for Adolescents With Type 1 Diabetes. Diabetes Care 2008, 32: 387-393. PMID: 19106380, PMCID: PMC2646014, DOI: 10.2337/dc08-0800.Peer-Reviewed Original ResearchConceptsMultiple daily injectionsInsulin glargineType 1 diabetesGlucose variabilityLente insulinPediatric patientsDaily injectionsBasal insulin componentOpen-label studySubset of patientsContinuous glucose monitoring systemMDI regimenGlucose monitoring systemGlycemic excursionsInsulin componentInsulin lisproContinuous glucose monitoring dataGlargineGlucose valuesGlucose monitoring dataType 1PatientsInsulinGreater reductionDiabetesPast, present, and future of insulin pump therapy: better shot at diabetes control
Sherr J, Tamborlane WV. Past, present, and future of insulin pump therapy: better shot at diabetes control. Annals Of Global Health 2008, 75: 352-361. PMID: 18729180, PMCID: PMC2562271, DOI: 10.1002/msj.20055.Peer-Reviewed Original ResearchConceptsPump therapyDiabetes controlContinuous subcutaneous insulin infusion (CSII) therapySubcutaneous insulin infusion therapyContinuous subcutaneous insulin infusionInsulin pump therapyInsulin infusion therapySubcutaneous insulin infusionType 1 diabetesComplications TrialInfusion therapyInsulin infusionIntensive treatmentPump useTherapyArtificial pancreasContinuous glucose sensorsDelivery systemFindingsSelection criteriaPatientsDiabetesInfusionPancreasNew findings
2006
Continuous subcutaneous insulin infusion (CSII) in children with type 1 diabetes
Tamborlane WV, Sikes KA, Steffen AT, Weinzimer SA. Continuous subcutaneous insulin infusion (CSII) in children with type 1 diabetes. Diabetes Research And Clinical Practice 2006, 74: s112-s115. PMID: 17182301, DOI: 10.1016/s0168-8227(06)70011-0.Peer-Reviewed Original ResearchConceptsContinuous subcutaneous insulin infusionSubcutaneous insulin infusionType 1 diabetesInsulin infusionEfficacy of CSIIExcessive weight gainInsulin pump therapyNew insulin analoguesQuality of lifePediatric patientsSevere hypoglycemiaHemoglobin levelsPump therapyTreatment optionsClinical studiesInsulin analoguesWeight gainDiabetesInfusionChildrenRecent studiesSafetyHypoglycemiaPatientsTherapy
2005
Disease Management in the Young Diabetic Patient: Glucose Monitoring, Coping Skills, and Treatment Strategies
Weinzimer SA, Doyle EA, Tamborlane WV. Disease Management in the Young Diabetic Patient: Glucose Monitoring, Coping Skills, and Treatment Strategies. Clinical Pediatrics 2005, 44: 393-403. PMID: 15965545, DOI: 10.1177/000992280504400503.Peer-Reviewed Original ResearchMeSH KeywordsAdaptation, PsychologicalAdolescentAdolescent BehaviorAdultAge FactorsAgedAttitude to HealthBlood GlucoseBlood Glucose Self-MonitoringChildDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2FemaleHumansHypoglycemic AgentsInjections, SubcutaneousInsulinInsulin ResistanceMaleMiddle AgedPatient CompliancePatient Education as TopicPrognosisRisk AssessmentSeverity of Illness IndexTreatment OutcomeConceptsYoung diabetic patientsGlycemic controlDiabetic patientsType 1 diabetes mellitusContinuous subcutaneous insulin infusionPresence of hypoglycemiaSubcutaneous insulin infusionType 2 diabetesDisease managementContinuous glucose-monitoring systemPositive treatment outcomesGlucose-monitoring systemInsulin glargineYounger patientsDiabetes mellitusHypoglycemic episodesJuvenile patientsNocturnal hypoglycemiaInsulin infusionTreatment outcomesTreatment strategiesCareful monitoringDiabetesPatientsGlucose monitoring
1988
Insulin Resistance and Hyperinsulinemia in Patients with Thalassemia Major Treated by Hypertransfusion
Merkel PA, Simonson DC, Amiel SA, Plewe G, Sherwin RS, Pearson HA, Tamborlane WV. Insulin Resistance and Hyperinsulinemia in Patients with Thalassemia Major Treated by Hypertransfusion. New England Journal Of Medicine 1988, 318: 809-814. PMID: 3281000, DOI: 10.1056/nejm198803313181303.Peer-Reviewed Original ResearchConceptsInsulin resistanceInsulin levelsThalassemia majorInsulin-stimulated glucose metabolismC-peptide levelsDevelopment of diabetesOral glucose administrationPlasma insulin levelsHypertransfusion therapyPubertal patientsPrepubertal patientsDiabetes mellitusGlucose toleranceInsulin deficiencyPubertal childrenGlucose administrationInsulin secretionIron overloadPrepubertal childrenChelation therapyPubertal subjectsGlucose metabolismBeta cellsHyperglycemic stimulusPatients